tag:www.gov.uk,2005:/drug-safety-update Drug Safety Update about Dentistry 2024-02-20T11:01:30+00:00 HM Government tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-january-2024 2024-02-20T11:01:30+00:00 Letters and medicine recalls sent to healthcare professionals in January 2024 A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-april-2023 2023-05-25T10:53:17+01:00 Letters and medicine recalls sent to healthcare professionals in April 2023 Recent MHRA National Patient Safety Alerts to remove from service Philips Health Systems V60 and V60 Plus ventilators and to recall Emerade adrenaline auto-injectors from patients, pharmacies and wholesalers. We also provide� tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-march-2022 2022-04-19T14:27:17+01:00 Letters and medicine recalls sent to healthcare professionals in March 2022 A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. Includes a recent recall of Accuretic (quinapril hydrochloride and hydrochlorothiazide). tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-june-2019 2019-07-17T13:34:54+01:00 Letters and drug alerts sent to healthcare professionals in June 2019 Letters were sent about Myocrisin (sodium aurothiomalate), Cerliponase alfa (Brineura�), Darzalex�(daratumumab), retinoids�, and febuxostat (Adenuric). A recall alert was issued for medicines that were taken out of the regul� tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-march-2019 2019-04-16T15:53:23+01:00 Letters and drug alerts sent to healthcare professionals in March 2019 Letters were sent about Xeljanz� (tofacitinib), ranitidine, Nulojix (belatacept), fluoroquinolone antibiotics, Genvoya�, Stribild�, Tybost, and belimumab (Benlysta�). Drug alerts were issued about Accord losartan potassium c� tag:www.gov.uk,2005:/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects 2019-03-21T11:50:07+00:00 Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics. Fluoroquinolone treatment should be discont� tag:www.gov.uk,2005:/drug-safety-update/oral-lidocaine-containing-products-for-infant-teething-only-to-be-available-under-the-supervision-of-a-pharmacist 2018-12-13T11:02:00+00:00 Oral lidocaine-containing products for infant teething: only to be available under the supervision of a pharmacist Oral lidocaine-containing products for infant teething are only to be available under the supervision of a pharmacist so that parents and caregivers can receive guidance about managing infant teething symptoms. Non-medicinal� tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-october-2018 2018-11-14T11:48:53+00:00 Letters and drug alerts sent to healthcare professionals in October 2018 Letters were sent to healthcare professionals about Jext adrenaline autoinjectors, rivaroxaban, Ozurdex 700 micrograms intravitreal implant, sildenafil, hydrochlorothiazide, and Epilim Chronosphere (sodium valproate). We als� tag:www.gov.uk,2005:/drug-safety-update/medicines-taken-during-pregnancy-please-report-suspected-adverse-drug-reactions-including-in-the-baby-or-child-on-a-yellow-card 2018-07-17T14:35:39+01:00 Medicines taken during pregnancy: please report suspected adverse drug reactions, including in the baby or child, on a Yellow Card Report to the Yellow Card Scheme suspected adverse reactions associated with medicines taken during pregnancy experienced by women or the baby or child. Obstetricians and midwives have a particularly important role in provid� tag:www.gov.uk,2005:/drug-safety-update/letters-sent-to-healthcare-professionals-in-january-2018 2018-02-06T16:59:25+00:00 Letters sent to healthcare professionals in January 2018 Letters were sent about Buccolam (midazolam), misoprostol vaginal delivery system (Mysodelle), noradrenaline, Relenza (zanamivir), mycophenolate mofetil/mycophenolic acid, Flolan, and Fludara. tag:www.gov.uk,2005:/drug-safety-update/letters-sent-to-healthcare-professionals-in-november-2017 2017-12-14T15:29:14+00:00 Letters sent to healthcare professionals in November 2017 Letters were sent about eluxadoline (Truberzi), fingolimod (Gilenya), Bleo-Kyowa (bleomycin sulphate), Buccolam (midazolam), and ERWINASE. tag:www.gov.uk,2005:/drug-safety-update/miconazole-daktarin-over-the-counter-oral-gel-contraindicated-in-patients-taking-warfarin 2017-09-26T16:57:40+01:00 Miconazole (Daktarin): over-the-counter oral gel contraindicated in patients taking warfarin Patients taking warfarin should not use over-the-counter miconazole oral gel (Daktarin). If you plan to prescribe miconazole oral gel in a patient on warfarin, you should closely monitor them and advise that if they experien� tag:www.gov.uk,2005:/drug-safety-update/denosumab-prolia-xgeva-reports-of-osteonecrosis-of-the-external-auditory-canal 2017-06-21T09:54:51+01:00 Denosumab (Prolia, Xgeva�): reports of osteonecrosis of the external auditory canal Denosumab is associated with a risk of osteonecrosis of the jaw, osteonecrosis of the external auditory canal has also been reported with denosumab. tag:www.gov.uk,2005:/drug-safety-update/posaconazole-noxafil-tablets-and-oral-suspension-are-not-directly-interchangeable 2016-09-15T12:00:52+01:00 Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable Switching from posaconazole oral solution to tablets has resulted in cases of dose-related toxicity, whereas switching from tablets to oral solution has resulted in underdosing and lack of efficacy. tag:www.gov.uk,2005:/drug-safety-update/topical-miconazole-including-oral-gel-reminder-of-potential-for-serious-interactions-with-warfarin 2016-06-15T14:58:27+01:00 Topical miconazole, including oral gel: reminder of potential for serious interactions with warfarin In view of reports of serious bleeding events in patients taking miconazole and warfarin, we are considering further measures to minimise the risk of potentially serious interactions between miconazole and warfarin. tag:www.gov.uk,2005:/drug-safety-update/aflibercept-zaltrap-minimising-the-risk-of-osteonecrosis-of-the-jaw 2016-04-18T13:44:12+01:00 Aflibercept (Zaltrap�): minimising the risk of osteonecrosis of the jaw Dental examination and appropriate preventive dentistry should be considered before treatment, especially for patients also treated with an intravenous bisphosphonate. tag:www.gov.uk,2005:/drug-safety-update/letters-sent-to-healthcare-professionals-in-march-2016 2016-04-18T13:42:57+01:00 Letters sent to healthcare professionals in March 2016 In March 2016, letters were sent regarding SGLT2 inhibitors, insulin lispro, natalizumab, noradrenaline, radium-223 dichloride, aflibercept and idelalisib. tag:www.gov.uk,2005:/drug-safety-update/denosumab-xgeva-prolia-intravenous-bisphosphonates-osteonecrosis-of-the-jaw-further-measures-to-minimise-risk 2015-07-20T11:59:37+01:00 Denosumab (Xgeva�, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk Patient reminder cards about the risk of osteonecrosis of the jaw are being introduced; denosumab 120 mg is now contraindicated in patients with unhealed lesions from dental or oral surgery. tag:www.gov.uk,2005:/drug-safety-update/codeine-for-analgesia-restricted-use-in-children-because-of-reports-of-morphine-toxicity 2014-12-11T14:35:09+00:00 Codeine for analgesia: restricted use in children because of reports of morphine toxicity Codeine should only be used to relieve acute moderate pain in children older than 12 years and only if it cannot be relieved by other painkillers such as paracetamol or ibuprofen alone. Furthermore, a significant risk of se� tag:www.gov.uk,2005:/drug-safety-update/codeine-restricted-use-as-analgesic-in-children-and-adolescents-after-european-safety-review 2014-12-11T14:34:52+00:00 Codeine: restricted use as analgesic in children and adolescents after European safety review tag:www.gov.uk,2005:/drug-safety-update/diclofenac-new-contraindications-and-warnings 2014-12-11T14:34:47+00:00 Diclofenac: new contraindications and warnings New recommendations after a Europe-wide review of cardiovascular safety. tag:www.gov.uk,2005:/drug-safety-update/black-triangle-medicines-part-of-an-eu-wide-scheme 2014-12-11T14:34:45+00:00 Black Triangle (�) medicines part of an EU-wide scheme Remember to report any suspected adverse reactions tag:www.gov.uk,2005:/drug-safety-update/recent-drug-name-confusion 2014-12-11T14:34:29+00:00 Recent drug-name confusion Please be vigilant as life-threatening errors may occur tag:www.gov.uk,2005:/drug-safety-update/reporting-suspected-adverse-drug-reactions-to-vaccines-and-biological-medicines 2014-12-11T14:34:00+00:00 Reporting suspected adverse drug reactions to vaccines and biological medicines The non-identical nature of biological medicines and vaccines means it is very important that safety surveillance is carried out on a brand/product-specific basis. tag:www.gov.uk,2005:/drug-safety-update/levofloxacin-some-indications-restricted 2014-12-11T14:33:30+00:00 Levofloxacin: some indications restricted Levofloxacin (a fluoroquinolone antibiotic) is unfavourable as first-line treatment for several indications. tag:www.gov.uk,2005:/drug-safety-update/chlorhexidine-reminder-of-potential-for-hypersensitivity 2014-12-11T14:32:38+00:00 Chlorhexidine: reminder of potential for hypersensitivity Healthcare professionals are reminded that chlorhexidine is known to induce hypersensitivity, including generalised allergic reactions and anaphylactic shock. tag:www.gov.uk,2005:/drug-safety-update/paracetamol-reminder-of-updated-dosing-recommendations-for-children 2014-12-11T14:32:15+00:00 Paracetamol: reminder of updated dosing recommendations for children Reminder that paediatric paracetamol liquids had been developed to ensure children receive optimum dosing for their age. tag:www.gov.uk,2005:/drug-safety-update/paracetamol-updated-dosing-for-children-to-be-introduced 2014-12-11T14:31:13+00:00 Paracetamol: updated dosing for children to be introduced Updated dosing for paediatric paracetamol liquids has been developed to ensure children receive the optimum dose for their age. tag:www.gov.uk,2005:/drug-safety-update/time-to-report 2014-12-11T14:31:10+00:00 Time to report A reminder to healthcare professionals to fill out Yellow Card reports. tag:www.gov.uk,2005:/drug-safety-update/bevacizumab-and-sunitinib-risk-of-osteonecrosis-of-the-jaw 2014-12-11T14:30:22+00:00 Bevacizumab and sunitinib: risk of osteonecrosis of the jaw Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib. tag:www.gov.uk,2005:/drug-safety-update/warfarin-product-information-to-be-amended-to-give-clearer-up-to-date-advice 2014-12-11T14:28:02+00:00 Warfarin: product information to be amended to give clearer, up-to-date advice We continue to receive a substantial number of serious and fatal adverse event reports for warfarin through our Yellow Card Scheme. tag:www.gov.uk,2005:/drug-safety-update/bisphosphonates-osteonecrosis-of-the-jaw 2014-12-11T14:27:49+00:00 Bisphosphonates: osteonecrosis of the jaw All patients with cancer should have a dental check-up before bisphosphonate treatment. tag:www.gov.uk,2005:/drug-safety-update/over-the-counter-painkillers-containing-codeine-or-dihydrocodeine 2014-12-11T14:27:21+00:00 Over-the-counter painkillers containing codeine or dihydrocodeine The tighter controls being introduced to minimise risk of overuse and or addiction of painkillers containing codeine or dihydrocodeine. tag:www.gov.uk,2005:/drug-safety-update/oral-salicylate-gels-not-for-use-in-those-younger-than-age-16-years 2014-12-11T14:26:47+00:00 Oral salicylate gels: not for use in those younger than age 16 years Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers. tag:www.gov.uk,2005:/drug-safety-update/counterfeit-medicines-what-pharmacists-should-know 2014-12-11T14:26:45+00:00 Counterfeit medicines: what pharmacists should know How pharmacists can prevent counterfeits reaching patients. tag:www.gov.uk,2005:/drug-safety-update/the-black-triangle-scheme-or 2014-12-11T14:26:43+00:00 The Black Triangle Scheme (� or �*) Continued monitoring of medicines with a black triangle status. tag:www.gov.uk,2005:/drug-safety-update/off-label-or-unlicensed-use-of-medicines-prescribers-responsibilities 2014-12-11T14:26:23+00:00 Off-label or unlicensed use of medicines: prescribers� responsibilities Healthcare professionals may have more responsibility to accurately prescribe an unlicensed medicine or an off-label medicine than when they prescribe a medicine within the terms of its licence. tag:www.gov.uk,2005:/drug-safety-update/central-alerting-system-cas-access-to-urgent-safety-guidance 2014-12-11T14:25:40+00:00 Central alerting system (CAS): access to urgent safety guidance Use the central alerting system to view and search new alerts, as well as past alerts that were issued through the public health link and safety alert broadcast system. tag:www.gov.uk,2005:/drug-safety-update/ecoflac-infusion-solutions-risk-of-air-embolism 2014-12-11T14:24:01+00:00 Ecoflac infusion solutions: risk of air embolism To avoid the risk of air embolism, these products should not be infused under pressure. tag:www.gov.uk,2005:/drug-safety-update/corticosteroids-early-psychiatric-side-effects 2014-12-11T14:23:40+00:00 Corticosteroids: early psychiatric side-effects Risk of early psychiatric side-effects is one of several important safety issues for healthcare professionals to discuss with patients and carers, who should seek urgent medical advice in the event of any worrying symptoms.